IRIS
POROTTO, Matteo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 4.352
NA - Nord America 2.812
AS - Asia 2.224
SA - Sud America 506
Continente sconosciuto - Info sul continente non disponibili 120
AF - Africa 35
OC - Oceania 1
Totale 10.050
Salva come PNG Salva come JPEG
Nazione #
RU - Federazione Russa 3.043
US - Stati Uniti d'America 2.748
SG - Singapore 932
IE - Irlanda 546
BR - Brasile 435
CN - Cina 398
HK - Hong Kong 313
IT - Italia 259
KR - Corea 220
VN - Vietnam 212
GB - Regno Unito 179
UA - Ucraina 126
GR - Grecia 58
DE - Germania 56
AR - Argentina 36
IN - India 35
BD - Bangladesh 28
CA - Canada 25
FR - Francia 17
ID - Indonesia 15
EC - Ecuador 13
FI - Finlandia 12
JP - Giappone 12
MX - Messico 12
IQ - Iraq 11
ZA - Sudafrica 11
SA - Arabia Saudita 8
UZ - Uzbekistan 8
CO - Colombia 7
JM - Giamaica 7
TR - Turchia 7
AT - Austria 6
ES - Italia 6
MA - Marocco 6
NL - Olanda 6
CR - Costa Rica 5
CZ - Repubblica Ceca 5
EG - Egitto 5
HN - Honduras 5
PL - Polonia 5
PY - Paraguay 5
TN - Tunisia 5
CL - Cile 4
PK - Pakistan 4
SE - Svezia 4
AL - Albania 3
BE - Belgio 3
BY - Bielorussia 3
CH - Svizzera 3
JO - Giordania 3
KE - Kenya 3
KG - Kirghizistan 3
MY - Malesia 3
NI - Nicaragua 3
VE - Venezuela 3
CG - Congo 2
GT - Guatemala 2
LK - Sri Lanka 2
NP - Nepal 2
PT - Portogallo 2
UY - Uruguay 2
AG - Antigua e Barbuda 1
AM - Armenia 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BG - Bulgaria 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EE - Estonia 1
HR - Croazia 1
HU - Ungheria 1
IL - Israele 1
KW - Kuwait 1
LT - Lituania 1
MD - Moldavia 1
MN - Mongolia 1
MV - Maldive 1
NG - Nigeria 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PE - Perù 1
PS - Palestinian Territory 1
RO - Romania 1
SN - Senegal 1
SV - El Salvador 1
SY - Repubblica araba siriana 1
TT - Trinidad e Tobago 1
Totale 9.930
Salva come PNG Salva come JPEG
Città #
Moscow 1.162
Dublin 519
San Jose 436
Santa Clara 414
Singapore 374
Hong Kong 311
Jacksonville 236
Seoul 220
Ashburn 197
Council Bluffs 184
New York 97
Chandler 96
Princeton 76
Roxbury 76
Ho Chi Minh City 73
Beijing 65
Medford 63
Milan 59
Hanoi 51
Hefei 41
São Paulo 41
Des Moines 33
Menlo Park 32
Dallas 27
The Dalles 23
Jinan 21
Wilmington 21
Munich 20
Nanjing 19
Rome 19
Cambridge 18
Los Angeles 18
Naples 17
Rio de Janeiro 17
Shenyang 16
Bengaluru 15
Brasília 14
Redwood City 14
Miano 13
North Bergen 13
Orem 13
Cagliari 12
Memphis 12
Atlanta 10
Belo Horizonte 10
Caserta 10
Norwalk 10
Nuremberg 10
Tianjin 10
Chicago 9
Curitiba 9
Montreal 9
Da Nang 8
Fairfield 8
Haiphong 8
Quito 8
Turku 8
Boardman 7
Boston 7
Hebei 7
Mountain View 7
Ningbo 7
San Francisco 7
Tashkent 7
Tokyo 7
Biên Hòa 6
Bremen 6
Caxias do Sul 6
Guangzhou 6
Haikou 6
Hangzhou 6
Mexico City 6
Porto Alegre 6
Redmond 6
Shanghai 6
Zhengzhou 6
Ann Arbor 5
Brooklyn 5
Changsha 5
Falkenstein 5
Juiz de Fora 5
Lanzhou 5
Palermo 5
Taiyuan 5
Taizhou 5
Avellino 4
Baghdad 4
Bauru 4
Buffalo 4
Campinas 4
Columbus 4
Dhaka 4
Goiânia 4
Guarulhos 4
Hải Dương 4
Johannesburg 4
Manchester 4
Nanchang 4
Phoenix 4
Quận Một 4
Totale 5.552
Salva come PNG Salva come JPEG
Nome #
Analysis of a subacute sclerosing panencephalitis (SSPE) Genotype B3 virus from the 2009/10 South African measles epidemic shows hyperfusogenic F proteins contribute to measles virus infection in the brain 193
A rapid high-throughput assay for the identification of neutralizing antibodies and antiviral molecules against SARS-CoV-2 virus 163
Human parainfluenza virus evolution during lung infection of immunocompromised humans promotes viral persistence 159
Effective in Vivo Targeting of Influenza Virus through a Cell-Penetrating/Fusion Inhibitor Tandem Peptide Anchored to the Plasma Membrane 158
Measles virus bearing MIBE-derived fusion protein is pathogenic after infection via the respiratory route 156
Effects of single α-to-β residue replacements on recognition of an extended segment in a viral fusion protein 154
Circulating clinical strains of human parainfluenza virus reveal viral entry requirements for in vivo infection 149
Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum 145
Capturing a fusion intermediate of influenza hemagglutinin with a cholesterol-conjugated peptide, a new antiviral strategy for influenza virus 144
A neutralizing antibody prevents postfusion transition of measles virus fusion protein 137
Broad spectrum antiviral activity for paramyxoviruses is modulated by biophysical properties of fusion inhibitory peptides 137
A broad-spectrum antiviral targeting entry of enveloped viruses 135
Dual Inhibition of Human Parainfluenza Type 3 and Respiratory Syncytial Virus Infectivity with a Single Agent 134
A three-dimensional model of human lung development and disease from pluripotent stem cells 134
A general strategy to endow natural fusion-protein-derived peptides with potent antiviral activity 132
A second receptor binding site on human parainfluenza virus type 3 hemagglutinin-neuraminidase contributes to activation of the fusion mechanism 130
Antiviral activity of nitazoxanide against Morbillivirus infections 127
Biophysical properties and antiviral activities of measles fusion protein derived peptide conjugated with 25-hydroxycholesterol 125
Rapid and Flexible Platform To Assess Anti-SARS-CoV-2 Antibody Neutralization and Spike Protein-Specific Antivirals 125
Adaptation of human parainfluenza virus to airway epithelium reveals fusion properties required for growth in host tissue 124
Antiviral activity of gliotoxin, gentian violet and brilliant green against Nipah and Hendra virus in vitro 123
Authentic modeling of human respiratory virus infection in human pluripotent stem cell-derived lung organoids 122
A single amino acid alteration in the human parainfluenza virus type 3 hemagglutinin-neuraminidase glycoprotein confers resistance to the inhibitory effects of zanamivir on receptor binding and neuraminidase activity 120
A recombinant sialidase fusion protein effectively inhibits human parainfluenza viral infection in vitro and in vivo 118
Antiviral Lipopeptide-Cell Membrane Interaction Is Influenced by PEG Linker Length 118
Development and validation of a chemiluminescent immunodetection assay amenable to high throughput screening of antiviral drugs for Nipah and Hendra virus 117
Electron tomography imaging of surface glycoproteins on human parainfluenza virus 3: association of receptor binding and fusion proteins before receptor engagement 114
Molecular determinants of antiviral potency of paramyxovirus entry inhibitors 113
Decreased differentiation of erythroid cells exacerbates ineffective erythropoiesis in β-thalassemia 112
Synthetic protocells interact with viral nanomachinery and inactivate pathogenic human virus 109
Fatal measles virus infection prevented by brain-penetrant fusion inhibitors 108
Viral entry properties required for fitness in humans are lost through rapid genomic change during viral isolation 105
The pH-sensitive action of cholesterol-conjugated peptide inhibitors of influenza virus 105
Intranasal fusion inhibitory lipopeptide prevents direct-contact SARS-CoV-2 transmission in ferrets 104
Identification of a region in the stalk domain of the Nipah virus receptor binding protein that is critical for fusion activation 103
Mechanism of interference mediated by human parainfluenza virus type 3 infection 103
Molecular Features of the Measles Virus Viral Fusion Complex That Favor Infection and Spread in the Brain 102
Fusion promotion by a paramyxovirus hemagglutinin-neuraminidase protein: pH modulation of receptor avidity of binding sites I and II 101
Hamster organotypic modeling of SARS-CoV-2 lung and brainstem infection 101
Spring-loaded model revisited: Paramyxovirus fusion requires engagement of a receptor binding protein beyond initial triggering of the fusion protein 100
Characterization of a SARS-CoV-2 Omicron BA.5 direct-contact transmission model in hamsters 99
Paramyxovirus receptor-binding molecules: Engagement of one site on the hemagglutinin-neuraminidase protein modulates activity at the second site 99
Measles fusion machinery is dysregulated in neuropathogenic variants 99
Simulating henipavirus multicycle replication in a screening assay leads to identification of a promising candidate for therapy 99
Prevention of measles virus infection by intranasal delivery of fusion inhibitor peptides 98
Fusion inhibitory lipopeptides engineered for prophylaxis of nipah virus in primates 97
Inhibiting Human Parainfluenza Virus Infection by Preactivating the Cell Entry Mechanism 97
Nebulized fusion inhibitory peptide protects cynomolgus macaques from measles virus infection 96
Rapid screening for entry inhibitors of highly pathogenic viruses under low-level biocontainment 95
Inhibition of parainfluenza virus type 3 and newcastle disease virus hemagglutinin-neuraminidase receptor binding: Effect of receptor avidity and steric hindrance at the inhibitor binding sites 95
Structure-Stability-Function Mechanistic Links in the Anti-Measles Virus Action of Tocopherol-Derivatized Peptide Nanoparticles 95
Absence of COVID-19-associated changes in plasma coagulation proteins and pulmonary thrombosis in the ferret model 94
Influence of the human parainfluenza virus 3 attachment protein's neuraminidase activity on its capacity to activate the fusion protein 94
SARS-CoV-2 infection and recovery in children: Distinct T cell responses in MIS-C compared to COVID-19 93
Interaction between the hemagglutinin-neuraminidase and fusion glycoproteins of human parainfluenza virus type III regulates viral growth in vivo 93
Mechanism of fusion triggering by human parainfluenza virus type III: Communication between viral glycoproteins during entry 93
Intermediates in SARS-CoV-2 spike-mediated cell entry 92
Viral entry inhibitors targeted to the membrane site of action 92
In Vivo Efficacy of Measles Virus Fusion Protein-Derived Peptides Is Modulated by the Properties of Self-Assembly and Membrane Residence 91
Inhibition of Nipah Virus Infection In Vivo: Targeting an early stage of paramyxovirus fusion activation during viral entry 91
The in vitro multilineage differentiation and maturation of lung and airway cells from human pluripotent stem cell-derived lung progenitors in 3D 91
Inhibition of Measles Viral Fusion Is Enhanced by Targeting Multiple Domains of the Fusion Protein 91
Quantitative analysis of molecular partition towards lipid membranes using surface plasmon resonance 90
Measles virus fusion machinery activated by sialic acid binding globular domain 90
Human parainfluenza virus type 3 HN-receptor interaction: Effect of 4-guanidino-neu5Ac2en on a neuraminidase-deficient variant 90
Features of circulating parainfluenza virus required for growth in human airway 90
Human parainfluenza virus infection of the airway epithelium: Viral hemagglutinin-neuraminidase regulates fusion protein activation and modulates infectivity 90
Design and evaluation of neutralizing and fusion inhibitory peptides to Crimean-Congo hemorrhagic fever virus 89
Inhibition of Hendra virus fusion 89
The second receptor binding site of the globular head of the newcastle disease virus hemagglutinin-neuraminidase activates the stalk of multiple paramyxovirus receptor binding proteins to trigger fusion 89
Inhibition of coronavirus entry in vitro and ex vivo by a lipid-conjugated peptide derived from the sars-cov-2 spike glycoprotein hrc domain 89
Triggering of human parainfluenza virus 3 fusion protein (F) by the hemagglutinin-neuraminidase (HN) protein: an HN mutation diminishes the rate of F activation and fusion 88
Unity in diversity: shared mechanism of entry among paramyxoviruses 88
Negative staining of proteins in polyacrylamide gels with methyl trichloroacetate 87
Single-chain variable fragment antibody constructs neutralize measles virus infection in vitro and in vivo 87
Kinetic dependence of paramyxovirus entry inhibition 86
Engineering Protease-Resistant Peptides to Inhibit Human Parainfluenza Viral Respiratory Infection 86
Development of nebulized inhalation delivery for fusion-inhibitory lipopeptides to protect non-human primates against Nipah-Bangladesh infection 85
Human parainfluenza virus fusion complex glycoproteins imaged in action on authentic viral surfaces 85
Structure-Guided Improvement of a Dual HPIV3/RSV Fusion Inhibitor 84
Modeling Infection and Tropism of Human Parainfluenza Virus Type 3 in Ferrets 82
Premature activation of the paramyxovirus fusion protein before target cell attachment with corruption of the viral fusion machinery 82
Hijacking the fusion complex of human parainfluenza virus as an antiviral strategy 82
In vivo antiviral host transcriptional response to SARS-CoV-2 by viral load, sex, and age 82
Improvement of HIV fusion inhibitor C34 efficacy by membrane anchoring and enhanced exposure infection 81
Regulation of paramyxovirus fusion activation, the hemagglutinin-neuraminidase protein stabilizes the fusion protein in a pretriggered state 80
Intranasally administrated fusion-inhibitory lipopeptides block SARS-CoV-2 infection in mice and enable long-term protective immunity 79
Repurposing an In Vitro Measles Virus Dissemination Assay for Screening of Antiviral Compounds 78
Modulation of Oncogenic DBL Activity by Phosphoinositol Phosphate Binding to Pleckstrin Homology Domain 77
How a paramyxovirus fusion/entry complex adapts to escape a neutralizing antibody 76
Functional properties of measles virus proteins derived from a subacute sclerosing panencephalitis patient who received repeated remdesivir treatments 75
Mutations in human parainfluenza virus type 3 hemagglutinin-neuraminidase causing increased receptor binding activity and resistance to the transition state sialic acid analog 4-GU-DANA (Zanamivir) 74
Early Permissiveness of Central Nervous System Cells to Measles Virus Infection Is Determined by Hyperfusogenicity and Interferon Pressure 73
Human parainfluenza virus 3 field strains undergo extracellular fusion protein cleavage to activate entry 69
Potency of Fusion-Inhibitory Lipopeptides against SARS-CoV-2 Variants of Concern 68
Enhancing the solubility of SARS-CoV-2 inhibitors to increase future prospects for clinical development 63
Subnanometer structure of an enveloped virus fusion complex on viral surface reveals new entry mechanisms 59
Host Cell Membrane Capture by the SARS-CoV-2 Spike Protein Fusion Intermediate 45
Totale 10.050
Salva come PNG Salva come JPEG
Categoria #
all - tutte 36.526
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 36.526
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022449 0 0 0 66 159 4 5 11 14 1 33 156
2022/2023673 80 1 0 7 57 36 0 33 426 3 14 16
2023/2024350 25 5 10 4 142 64 1 3 1 2 14 79
2024/20251.493 23 100 4 10 192 196 89 102 168 418 110 81
2025/20265.316 242 319 258 366 379 2.812 170 344 246 95 68 17
2026/2027964 46 82 407 429 0 0 0 0 0 0 0 0
Totale 10.050